Study of Proteins in Head and Neck Cancer Cells
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.
| Condition | Intervention |
|---|---|
|
Head and Neck Cancer |
Genetic: Southern blotting Genetic: TdT-mediated dUTP nick end labeling assay Genetic: gene expression analysis Genetic: protein expression analysis Other: flow cytometry Other: fluorescent antibody technique Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique |
| Study Type: | Observational |
| Official Title: | Novel Protein Regulator of Tumor Suppressor ARF & NF-κB |
- Function and mechanism of LZAP in regulating ARF [ Designated as safety issue: No ]
- Mechanism and biological consequences of LZAP inhibition of NF-κB [ Designated as safety issue: No ]
- Determination of LZAP tumor suppressor activity [ Designated as safety issue: No ]
| Study Start Date: | May 2005 |
OBJECTIVES:
- Define the function and mechanism of LZAP in regulating ARF.
- Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
- Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.
OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
- Head and neck cancer tumor cell line
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations| United States, Tennessee | |
| Vanderbilt-Ingram Cancer Center - Cool Springs | Recruiting |
| Nashville, Tennessee, United States, 37064 | |
| Contact: Wendell G Yarbrough 615-343-8840 | |
| Vanderbilt-Ingram Cancer Center at Franklin | Recruiting |
| Nashville, Tennessee, United States, 37064 | |
| Contact: Wendell G Yarbrough 615-343-8840 | |
| Vanderbilt-Ingram Cancer Center | Recruiting |
| Nashville, Tennessee, United States, 37232-6838 | |
| Contact: Clinical Trials Office - Vanderbilt-Ingram Cancer Center 800-811-8480 | |
| Study Chair: | Wendell G. Yarbrough, MD, FACS | Vanderbilt-Ingram Cancer Center |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00896948 History of Changes |
| Other Study ID Numbers: | CDR0000558974, VU-VICC-HN-0529, VU-VICC-IRB-050259 |
| Study First Received: | May 9, 2009 |
| Last Updated: | August 11, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
head and neck cancer |
Additional relevant MeSH terms:
|
Head and Neck Neoplasms Neoplasms by Site Neoplasms Antibodies |
Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013